510 related articles for article (PubMed ID: 22646492)
1. Evaluation of the role of the new INNOVANCE PFA P2Y test cartridge in detection of clopidogrel resistance.
Tsantes A; Ikonomidis I; Papadakis I; Kottaridi C; Tsante A; Kalamara E; Kardoulaki A; Kopterides P; Kapsimali V; Karakitsos P; Lekakis J; Travlou A
Platelets; 2012; 23(6):481-9. PubMed ID: 22646492
[TBL] [Abstract][Full Text] [Related]
2. The new INNOVANCE® PFA P2Y cartridge is sensitive to the detection of the P2Y₁₂ receptor inhibition.
Koessler J; Kobsar AL; Rajkovic MS; Schafer A; Flierl U; Pfoertsch S; Bauersachs J; Steigerwald U; Rechner AR; Walter U
Platelets; 2011; 22(1):20-7. PubMed ID: 20873965
[TBL] [Abstract][Full Text] [Related]
3. Assessment of clopidogrel non-response by the PFA-100 system using the new test cartridge INNOVANCE PFA P2Y.
Linnemann B; Schwonberg J; Rechner AR; Mani H; Lindhoff-Last E
Ann Hematol; 2010 Jun; 89(6):597-605. PubMed ID: 20049442
[TBL] [Abstract][Full Text] [Related]
4. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry.
Jakubowski JA; Payne CD; Li YG; Farid NA; Brandt JT; Small DS; Salazar DE; Winters KJ
Thromb Haemost; 2008 Jan; 99(1):215-22. PubMed ID: 18217157
[TBL] [Abstract][Full Text] [Related]
5. Prostacyclin receptor stimulation facilitates detection of human platelet P2Y(12) receptor inhibition by the PFA-100 system.
Kobsar AL; Koessler J; Rajkovic MS; Brunner KP; Steigerwald U; Walter U
Platelets; 2010; 21(2):112-6. PubMed ID: 20085435
[TBL] [Abstract][Full Text] [Related]
6. Poor agreement between light transmission aggregometry, Verify Now P2Y₁₂ and vasodilatator-stimulated phosphoprotein for clopidogrel low-response assessment: a potential explanation of negative results of recent randomized trials.
Lemesle G; Landel JB; Bauters A; Delhaye C; Bonello L; Sudre A; Susen S; Bauters C; Lablanche JM
Platelets; 2014; 25(7):499-505. PubMed ID: 24176022
[TBL] [Abstract][Full Text] [Related]
7. Doubling the clopidogrel dose in patients with reduced responsiveness to the standard dose is associated with a limited effectiveness as evaluated by impedance aggregometry.
Stellbaum C; Ayral Y; Morguet A; Schultheiss HP; Rauch U
Cardiovasc Revasc Med; 2012; 13(3):159-66. PubMed ID: 22503564
[TBL] [Abstract][Full Text] [Related]
8. Impact of the proton pump inhibitors and CYP2C19*2 polymorphism on platelet response to clopidogrel as assessed by four platelet function assays.
Tsantes AE; Ikonomidis I; Papadakis I; Bonovas S; Gialeraki A; Kottaridi C; Kyriakou E; Kokori S; Douramani P; Kopterides P; Karakitsos P; Lekakis J; Kapsimali V
Thromb Res; 2013 Aug; 132(2):e105-11. PubMed ID: 23830212
[TBL] [Abstract][Full Text] [Related]
9. The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent.
Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
Thromb Res; 2011 Oct; 128(4):352-7. PubMed ID: 21621250
[TBL] [Abstract][Full Text] [Related]
10. VerifyNow and VASP phosphorylation assays give similar results for patients receiving clopidogrel, but they do not always correlate with platelet aggregation.
Bidet A; Jais C; Puymirat E; Coste P; Nurden A; Jakubowski J; Nurden P
Platelets; 2010; 21(2):94-100. PubMed ID: 20148735
[TBL] [Abstract][Full Text] [Related]
11. Changes in response to clopidogrel therapy in patients after percutaneous coronary interventions as assessed by different platelet function tests.
Golański J; Syska K; Chiżynski K; Kassasir H; Watała C; Sakowicz A; Kuliczkowski W
Pol Arch Med Wewn; 2016 Aug; 126(9):653-661. PubMed ID: 27534914
[TBL] [Abstract][Full Text] [Related]
12. Ability of the INNOVANCE PFA P2Y system to detect clopidogrel-induced ADP receptor blockade in preangiocath individuals.
McGlasson DL; Shah AD; Fritsma GA
Blood Coagul Fibrinolysis; 2011 Oct; 22(7):583-7. PubMed ID: 21799401
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of ex vivo high on-treatment platelet reactivity on antiplatelet therapy after transient ischemic attack or ischemic stroke on the PFA-100(®) and VerifyNow(®).
Kinsella JA; Tobin WO; Cox D; Coughlan T; Collins R; O'Neill D; Murphy RP; McCabe DJ
J Stroke Cerebrovasc Dis; 2013 Oct; 22(7):e84-92. PubMed ID: 22981273
[TBL] [Abstract][Full Text] [Related]
14. The risk of false results in the assessment of platelet function in the absence of antiplatelet medication: comparison of the PFA-100, multiplate electrical impedance aggregometry and verify now assays.
Can MM; Tanboğa IH; Türkyilmaz E; Karabay CY; Akgun T; Koca F; Tokgoz HC; Keles N; Ozkan A; Bezgin T; Ozveren O; Sonmez K; Sağlam M; Ozdemir N; Kaymaz C
Thromb Res; 2010 Apr; 125(4):e132-7. PubMed ID: 19954823
[TBL] [Abstract][Full Text] [Related]
15. Point-of-care whole blood impedance aggregometry versus classical light transmission aggregometry for detecting aspirin and clopidogrel: the results of a pilot study.
Velik-Salchner C; Maier S; Innerhofer P; Streif W; Klingler A; Kolbitsch C; Fries D
Anesth Analg; 2008 Dec; 107(6):1798-806. PubMed ID: 19020120
[TBL] [Abstract][Full Text] [Related]
16. Multiple electrode aggregometry and vasodilator stimulated phosphoprotein-phosphorylation assay in clinical routine for prediction of postprocedural major adverse cardiovascular events.
Freynhofer MK; Brozovic I; Bruno V; Farhan S; Vogel B; Jakl G; Willheim M; Hübl W; Wojta J; Huber K
Thromb Haemost; 2011 Aug; 106(2):230-9. PubMed ID: 21614416
[TBL] [Abstract][Full Text] [Related]
17. The influence of clinical characteristics, laboratory and inflammatory markers on 'high on-treatment platelet reactivity' as measured with different platelet function tests.
Elsenberg EH; van Werkum JW; van de Wal RM; Zomer AC; Bouman HJ; Verheugt FW; Berg JM; Hackeng CM
Thromb Haemost; 2009 Oct; 102(4):719-27. PubMed ID: 19806258
[TBL] [Abstract][Full Text] [Related]
18. Comparison of conventional aggregometry with VASP for monitoring P2Y12-specific platelet inhibition.
Aradi D; Magyarlaki T; Tokés-Füzesi M; Rideg O; Vorobcsuk A; Komócsi A
Platelets; 2010; 21(7):563-70. PubMed ID: 20642320
[TBL] [Abstract][Full Text] [Related]
19. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation.
Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
Thromb Haemost; 2009 Feb; 101(2):333-9. PubMed ID: 19190818
[TBL] [Abstract][Full Text] [Related]
20. [Evaluation of PFA P2Y assay in monitoring platelet function in elderly patients with cardiovascular disease receiving clopidogrel treatment].
Tian KP; Guan J; Cai LL; Li YR; Deng XL; Liu QY; Zheng BX; Cong YL
Nan Fang Yi Ke Da Xue Xue Bao; 2016 Apr; 37(4):533-536. PubMed ID: 28446409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
